Mohammad AskarPublic working copy · medical review pending

Conventional glaucoma surgery · 206

Conventional glaucoma surgery: target, selection and aftercare

Choose surgery from documented progression, target pressure and the risks of the actual eye. Technical examples require individual planning and specialist training.

Public working copy · medical review pending. Source, translation and medical checks remain open. Read the limitations in the text and references. These educational materials do not replace individual medical assessment. Published: 2026-11-18T19:45:52+01:00. Internal project references lead to this notice. They are not publicly accessible primary sources; the source limitations remain stated in the text.

Trabeculectomy, non-penetrating surgery and tubes have different trade-offs. Match the population and meaningful outcomes, then secure lifelong follow-up.

Terminology and draft status

Terminology review is not complete. Selected actual WHO UMD queries and their limits are recorded in terminology.md; they do not approve the whole translation.

01Choose the goal and timing

Glaucoma surgery aims to preserve remaining vision by lowering intraocular pressure (IOP); it cannot restore established optic-nerve damage. IOP is a modifiable treatment target and a surrogate: visual-field progression, vision, quality of life and treatment burden also matter. A plumbing analogy can explain drainage, but does not capture neural injury or guarantee a cure. No procedure is a universal solution. 1 2

Document glaucoma subtype, angle by gonioscopy, visual field, optic nerve/OCT, rate of progression, baseline and treated IOP, corneal factors, fellow-eye function, lens status, conjunctiva and prior operations. Include medication tolerance, adherence, patient preference and ability to attend follow-up. Surgery may be appropriate when medication/laser is unlikely to preserve sight; exhausting every drop is not a prerequisite. For advanced disease TAGS supports discussing primary trabeculectomy, rather than imposing a rigid last-resort ladder. 1 2

Set and reassess a target for each eye, accounting for damage, progression, remaining lifetime, starting pressure and treatment risk. An advanced eye may need a substantially lower pressure than a mildly affected eye. Neither <15 mmHg nor a single stage threshold is a universal prescription; progression despite reaching the current target requires reassessment. 1

The original stage examples 15–18 mmHg for mild loss to −6 dB,12–15 mmHg for moderate−6 to−12 dB and low-teens/single digits for advanced disease are not universal targets. With the usual negative Humphrey MD convention, more advanced loss is below−12 dB, not the original >−12 dB. The original 6–21 mmHg range, planning to 110 years and 30–50% reduction are examples without an individual prognosis; compare age 40 versus 90 without assuming age alone dictates surgery. 11 1

02Assess scarring and tissue vulnerability before technique

Conjunctival surgery, chronic topical exposure, inflammation and healing tendency affect filtration planning. Ancestry is a population association, not an individual scar diagnosis or a requirement for MMC. The original IL-2 mechanism and mandatory steroid preparation are not independently established here; assess the actual ocular surface and inflammation. 11 12

Uveitis increases management complexity but does not imply nearly 100% trabeculectomy failure or automatic tube superiority. Control inflammation and consider prior surgery, conjunctiva and target. Rheumatoid disease or suspected scleral thinning requires assessment of tissue integrity; neither RA nor a named diagnosis alone establishes inevitable scleral melt or an identical antimetabolite policy. 11 12

03Describe the operation as controlled flow and wound healing

Trabeculectomy creates a guarded anterior-chamber/subconjunctival fistula. Peritomy, scleral flap, sclerostomy and selected peripheral iridectomy need secure tissue handling and lens protection. The original sub-Tenon anaesthetic/saline “Genwin” ballooning and named Moorfields forceps remain teaching examples with unresolved exact source; toothed forceps do not make every operation fail, and no single instrument removes all buttonhole risk. 11 12

MMC concentration, area, application method and exposure are individual decisions. Original 0.2–0.4 mg/ml for 3–4 minutes and mandatory 100 ml saline are not universal rules. EGS lists 0.1–0.5 mg/ml,1–5 minutes for sponge exposure and at least 10–20 ml balanced-salt rinsing; these source ranges are not a preparation recipe and do not replace the actual product/local protocol. Prevent intraocular entry and exposure of cut conjunctival edges; greater exposure can increase hypotony and thin-bleb/infection risk. 11 12

Flap thickness 1/2–2/3 of sclera and no spontaneous flow at 20–25 mmHg with flow on gentle pressure are original technical examples, not a validated universal “Goldilocks” target. Adjust flap geometry and fixed/releasable/adjustable sutures to anatomy and controlled flow; test wound closure. Peripheral iridectomy addresses iris obstruction risk but is not a guarantee against every blockage or lens injury. 11 12

Deep sclerectomy removes deeper sclera and unroofs Schlemm canal while preserving a trabeculo-Descemet barrier; it is not simply filtration through bare Descemet alone. The original 25–30% reduction is not a universal comparative effect. A perforation requires judgement about size, iris/chamber involvement and conversion; not every microperforation mandates an identical immediate trabeculectomy. 11 12 8

04Read bleb surgery and tube evidence by population

Trabeculectomy with antifibrotic treatment can achieve low pressures and remains a key option for advanced disease. Tubes are important with prior surgery, scarring or high filtration-failure risk. PTVT and TVT studied different surgical histories: compare populations before declaring a winner. Ahmed/Baerveldt evidence shows lower pressure with Baerveldt but more hypotony-related failure; it cannot be transferred to every tube design. No source verifies the original resident-versus-expert explanation dismissing Bascom Palmer results. Surgeon expertise matters but is not evidence that a trial result is invalid. 2 3 4 7

Deep sclerectomy and viscocanalostomy preserve different tissue barriers from trabeculectomy; postoperative goniopuncture may be part of treatment. The older Cochrane review included five small, methodologically limited trials: it did not establish deep-sclerectomy equivalence to trabeculectomy. Cyclophotocoagulation reduces aqueous production; technique and visual potential affect selection. Inflammation, hypotony, vision loss and retreatment remain relevant; it is neither restricted categorically to blind eyes nor interchangeable with every drainage procedure. 1 8

Ahmed has a valve, but the original opening near 8 mmHg is not a guaranteed clinical floor or freedom from hypotony. Baerveldt and Paul are non-valved; selected ligation and/or intraluminal stenting restrict early flow. Device/anatomy-specific plate location, tube route and coverage matter; original 10 mm behind the limbus is not the correct position for every model or child, and a RIP/rip-cord is not the same as every dissolving ligature. 11 12 7

05Plan healing, drops and urgent access

Aftercare is part of surgery: assess IOP, vision, anterior-chamber depth, inflammation, wounds/bleb, implant position and cornea. Early low pressure requires identifying leak, overfiltration or other cause; high pressure requires identifying retained viscoelastic, hyphema, steroid response, obstruction or scarring. A shallow chamber, infection or vision deterioration needs prompt specialist assessment. Bleb massage, suture adjustment, needling and 5-FU/MMC are selected interventions, not routine instructions for every patient. Risks include hypotony maculopathy, choroidal complications, tube exposure and late bleb infection. Follow-up remains individualized and long term. 1 3 5 6

The operation lowers pressure to protect remaining sight; drops or further procedures may still be needed. Attend scheduled checks and follow the individually prescribed drops and restrictions on rubbing, lifting and water exposure; duration is operation-specific. Severe pain, increasing redness, discharge or sudden visual loss requires immediate contact with the surgical team/emergency eye service. Late infection can occur months or years after bleb surgery. Educational information does not replace examination or individualized treatment. 9

Before a Schlemm-canal procedure, confirm an accessible open angle with gonioscopy and assess the target, severity, prior surgery and ability to attend follow-up. After surgery, tailor anti-inflammatory treatment and review pressure, wound, chamber and device/bleb findings. A filtering bleb needs lifelong education about infection symptoms and urgent access; a nonoperative follow-up consensus interval is not the postoperative schedule or the early pressure check after laser. 10

A white infiltrated bleb with redness, pain or reduced vision requires urgent assessment for blebitis and endophthalmitis. Original 6/12 is not a diagnostic cutoff, and 12-hour reviews or moxifloxacin alone must not delay appropriate sampling, intravitreal treatment and specialist care when intraocular infection is suspected. Clinical involvement, not one visual-acuity value, guides escalation. 11 12

Symptomatic overhanging blebs may need selected compression sutures or revision after assessing flow, leak and surface injury. The original name Bomberg remains unresolved rather than silently renamed; compression is not an automatic way to preserve all fistula function without hypotony or pressure-rise risk. 11

06Compare results, costs and uncertainty

TAGS,5 y Primary trabeculectomy/medical treatment;453 new advanced OAG patients IOP 12.07/14.76 mmHg; adjusted difference−2.56 (95% CI−3.80 to −1.32). VFQ-25 difference 1.01(−1.99 to 4.00), p=0.51; better field preservation with surgery. Not proof of QoL superiority; treatment unmasked; advanced newly diagnosed population. 2

PTVT,5 y Baerveldt 350/trab+MMC;242 eyes without prior incisional surgery Failure 42%/35%, p=0.21; IOP 13.4/13.0; medications 2.2/1.3. Nonsignificant failure difference is not equivalence; differs from TVT. 3

TVT,5 y Tube/trab+MMC; previous cataract surgery and/or failed trab Failure 29.8%/46.9%, p=0.002. Not primary-surgery PTVT population; not a universal NVG rule. 4

Ahmed/Baerveldt,5 y Pooled twoRCTs;514 eyes with failed/high-risk trab IOP 15.8/13.2; failure 49%/37%, p=0.007; hypotony failure 0.4%/4.5%. Device/population-specific trade-off; not evidence for every tube including Paul. 7

Compare results, costs and uncertainty
ProcedureSelectionOriginal pressure estimatePossible advantageImportant riskEvidence limit
TrabeculectomySelected advanced OAGUp to 50%, not a guaranteeLow achievable targetHypotony/leak/bleb infectionTAGS pressure/field benefit is not QoL superiority
Deep sclerectomySelected open-angle diseaseOriginal 25–30%, context dependentFewer hypotony-related complicationsPerforation/insufficient pressure loweringNo established equivalence to trabeculectomy
AhmedSelected refractory/secondary disease or childrenVariableEarly flow through valveHypertensive phase/corneal injury/hypotonyNo universal NVG or paediatric superiority
Baerveldt /PaulSelected scarring/reoperation/uveitis riskVariable, not maximal in every eyeLong-term drainageEarly hypotony/implant exposureRestrict early flow; evidence is device-specific
What are the main learning points?

Trabeculectomy, non-penetrating surgery and tubes have different trade-offs. Match the population and meaningful outcomes, then secure lifelong follow-up.

When is assessment urgent?

After surgery, severe pain, increasing redness, discharge, a shallow chamber or sudden visual loss needs urgent contact with the surgical team. Late bleb infection is also an emergency.

References and access status

  1. 1
    EGS 6 (2025), professional guideline; full text inspected, pp.22–24,163–164,192–202.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 004 source appraisal of 1 October 2026 reused; scope is stated in the title and source dossier, not fresh full-source access.

  2. 2
    TAGS 5-year RCT: primary trabeculectomy versus medication, newly diagnosed advanced OAG.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 004 source appraisal of 1 October 2026 reused; scope is stated in the title and source dossier, not fresh full-source access.

  3. 3
    PTVT 5-year RCT: Baerveldt 350 versus trabeculectomy+MMC, no previous incisional ocular surgery.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 004 source appraisal of 1 October 2026 reused; scope is stated in the title and source dossier, not fresh full-source access.

  4. 4
    TVT 5-year RCT: tube versus trabeculectomy, previous cataract surgery and/or failed filtration.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 004 source appraisal of 1 October 2026 reused; scope is stated in the title and source dossier, not fresh full-source access.

  5. 5
    MicroShunt versus trabeculectomy, randomized noninferiority trial,2 years.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 004 source appraisal of 1 October 2026 reused; scope is stated in the title and source dossier, not fresh full-source access.

  6. 6
    XEN 45 GPS POAG subgroup, randomized study 12 months,2025.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 004 source appraisal of 1 October 2026 reused; scope is stated in the title and source dossier, not fresh full-source access.

  7. 7
    Ahmed versus Baerveldt pooled randomized 5-year evidence.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 004 source appraisal of 1 October 2026 reused; scope is stated in the title and source dossier, not fresh full-source access.

  8. 8
    Deep sclerectomy/viscocanalostomy versus trabeculectomy, Cochrane 2014.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 004 source appraisal of 1 October 2026 reused; scope is stated in the title and source dossier, not fresh full-source access.

  9. 9
    Immutable original export; MIGS/MIBS original; own table/video preserved

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  10. 10
    AAO. Glaucoma Summary Benchmarks for Preferred Practice Pattern Guidelines (December 2025), pp. 1–9.

    Historical 187-glaucoma-surgery appraisal reused; not new full-source access. Historical 005 supplied benchmark PDF access 6 October 2026 reused; current direct AAO request returned 403 on 16 November 2026. Not a new full-PDF/PPP appraisal; exact current operative pages and product/local protocols remain open.

  11. 11
    Immutable original export; own conventional surgery lecture; examiner identity unverified

    Complete export read; original attribution and any recording/transcript or appointment not independently verified.

  12. 12
    EGS 6 selected surgery/antifibrotic text pp 194–196,203–204

    Selected locally cached text read 17 November 2026: trabeculectomy/NPGS/GDDs and individual antifibrotic precautions/MMC exposure/rinsing; not a fresh whole-book or product-IFU review.

Original lecture link